
United Hospital Center honored for commitment to health care sustainability
Stryker's Sustainability Solutions presented WVU Medicine United Hospital Center with its Environmental Excellence Award for demonstrating leadership in health care "sustainability and overall hospital quality through single-use device reprocessing," according to a hospital press release.
Single-use processing involves cleaning, disinfecting, and sterilizing devices that are intended for single use after they have been used on a patient and then reusing them. In 2024, the UHC reprocessing program successfully diverted 1,184 pounds of medical waste from landfills due to its reprocessing program that is supported by Stryker.
In health care, reprocessing refers to the process of cleaning, disinfecting, or sterilizing reusable medical devices to ensure they are safe for reuse on other patients. This practice is essential to minimize the risk of healthcare-associated infections and other adverse health outcomes. Reprocessing involves a series of steps, including initial decontamination, thorough cleaning, and either disinfection or sterilization, depending on the device's intended use and the materials from which it's made.
'Stryker is pleased to honor UHC's continued dedication to achieving both environmental and financial sustainability,' Natalie Ward, vice president and general manager of Stryker's Sustainability Solutions, said. 'With a heightened focus on improving value in today's healthcare environment, UHC leads by example with their commitment to sustainability initiatives that reduce costs and optimize resources in order to support quality care.'
Leading hospitals across the nation are continuing to pursue initiatives to reduce the environmental impact of health care delivery. Among these initiatives, single-use device reprocessing stands out as an environmental practice that not only dramatically reduces the amount of medical waste, but, at the same time, it frees significant resources for the hospital — all without capital investment.
'In today's health care environment, there is a heightened focus to minimize the environmental footprint,' Liberty Kincaid, manager of supply chain utilization at UHC, said. 'At UHC, we are committed to sustainability and environmental stewardship, all while continuing to provide excellent care to our patients.'
UHC is in the distinguished company of other leading hospitals that are implementing reprocessing programs, which are currently employed by nearly all the U.S. News & World Report 'Honor Roll' hospitals.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
14-07-2025
- Associated Press
Surgical stroke initiative targets deadliest brain bleeds
( NewMediaWire ) - July 14, 2025 - DALLAS — Hemorrhagic strokes account for just 13% of the nearly 800,000 strokes that occur in the U.S. each year, yet they are responsible for more than 40% of all stroke-related deaths. [1] These devastating brain bleeds have long lacked standardized surgical treatment protocols, limiting patient recovery options. In response, the American Heart Association, devoted to changing the future of health for all, is launching a new nationwide initiative to accelerate the adoption of effective surgical approaches, including minimally invasive techniques, to improve outcomes for people affected by intracerebral hemorrhage (ICH). The Hemorrhagic Stroke Surgical Quality Improvement Initiative, supported financially by Stryker, will identify and amplify national models of effective ICH care, including the use of minimally invasive parafascicular surgery (MIPS). MIPS is a minimally invasive procedure that uses a tubular retractor to navigate through the brain's natural folds, along with a powered instrument designed to remove clots and help prevent damage. Research has shown that when performed within 24 hours of a brain bleed, MIPS may lead to better recovery outcomes at six months compared to standard treatments. [2] 'The ability to share data and accelerate learning is critical to improving stroke care,' said Kevin Sheth, M.D., FAHA, American Heart Association volunteer, chair of the Association's ICH Science Advisory Group and director of the Yale Center for Brain & Mind Health. 'Through this initiative, we hope to reduce the devastating outcomes associated with hemorrhagic stroke by improving access to surgical interventions proven to improve patient recovery.' Fifteen hospitals across the U.S. will participate in a learning collaborative, using data from the Association's Get With The Guidelines(R) - Stroke registry, which tracks approximately three-quarters of the nation's stroke hospitalizations. These selected sites will analyze ICH care data and clinical workflows to identify successful models that could be scaled nationally: Criteria for site selection included demonstrated leadership in MIPS, infrastructure readiness and interest in expanding ICH surgical options. For more information, visit Additional Resources: ### About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries: 214-706-1173 Michelle Rosenfeld: [email protected] For Public Inquiries: 1-800-AHA-USA1 (242-8721) and [1]Stroke Facts. Centers for Disease Control and Prevention. October 24, 2024. Accessed May 28, 2025; Andersen K, et al. Hemorrhagic and Ischemic Strokes Compared: Stroke Severity, Mortality, and Risk Factors. Stroke. April 9, 2009. 40(6). [2] Pradilla G, et al. Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage. NEJM. April 10, 2024. 390(14):1277-1289.
Yahoo
10-07-2025
- Yahoo
Will medtech M&A pick back up in the second half?
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The medical device industry kicked off 2025 similarly to most years: Top companies were spending money. Stryker, Zimmer Biomet and Thermo Fisher Scientific all announced deals worth more than $1 billion, and Boston Scientific, after a rush of M&A last year, announced a pair of acquisitions that could collectively eclipse that mark. However, activity has since cooled, with few transactions taking place outside of the first two months of the year. 'The number of medtech M&A deals for the first half of the year, technically, is on pace to match last year's … but it has been really front-loaded,' said Aaron DeGagne, a senior healthcare analyst with PitchBook. Stryker's nearly $5 billion pickup of Inari Medical — the year's highest price tag so far — was announced Jan. 6. Rival Zimmer Biomet revealed it would buy Paragon 28 for $1.1 billion a few weeks later. And Thermo Fisher Scientific agreed to buy Solventum's purification and filtration business for $4.1 billion in February. Meanwhile, Boston Scientific's deal worth up to $664 million for the remaining stake of Bolt Medical and its purchase of Sonvie, worth up to $540 million, were announced in early January and March, respectively. Since then, the M&A environment has been quiet, with few acquisitions, let alone a billion-dollar or multi-billion-dollar purchase. Analysts said in interviews that the slowdown in dealmaking is due to similar factors as the slowdown in initial public offerings after a handful of companies went public in the span of a few months: economic uncertainty and an up-and-down market, largely due to the Trump administration's tariff policies. Companies tightened their pocketbooks as the market dropped and questions swirled about the impact of the Trump administration's trade strategy. 'Part of the reason for [the slowdown] is when you have these transactions, especially as they get into the hundreds of millions — and into the billions — these are deals that are being worked on for not just weeks, but usually worked on for months, or even years,' DeGagne said. 'When we get some of these deals announced in January, February, March — I think the ball got rolling on these either early this year or late last year, when I think the market was in a pretty good place.' Shagun Singh, an analyst with RBC Capital Markets, said companies wanted to see how the tariffs would affect their businesses shortly after the policies were announced, and that they wanted to 'see what the headwinds are, what they need to do, how they need to manage it.' The Trump administration's tariff policies have affected medtech companies in different ways — some saw little impact, while companies like Johnson & Johnson, Abbott and Boston Scientific projected charges worth hundreds of millions of dollars. Questions still exist about how businesses will move forward as trade tensions with China and other countries have, for now, eased. John Babitt, a partner with EY, added that deals announced in the first quarter, like Stryker's and Zimmer's, would have been 'a lot more difficult to get done post-tariff announcement.' With uncertainty looming around tariffs, specifically, buyers may value companies less if they are exposed to the trade policies, PitchBook's DeGagne said. He added that an uncertain and complex market in general forces companies to take a closer look at their spending, which can influence whether acquisitions will be made. 'Generally speaking, market uncertainty creates difficult business environments, and so a lot of these big public companies are scrutinizing their costs,' DeGagne said. 'They don't know if their customers are going to continue buying, and so … they will be less likely to, probably, go ahead with a high price transaction in that environment.' Dealmaking is expected to resume in the second half, the analysts said, as the economic environment stabilizes a bit more. After weathering a turbulent past few months, Singh said companies are 'back in a mood where they are thinking about their businesses and thinking about long-term strategies.' And while there is still uncertainty about the future of tariff policies and other macroeconomic factors, companies may still be willing to pull the trigger on M&A when the opportunity arises. 'I don't think there is expectation that the worst is behind us. I think there is uncertainty right now. I don't know if there's a good time,' Singh said. 'I think companies are going to be opportunistic.' EY's Babitt said that people are 'cautiously optimistic' that medtech firms will spend more later this year compared to the first half, adding that his company is seeing that sentiment in 'the activity in our business as well.' One strategy companies are using is a dual-process approach, where they are simultaneously pursuing a sale and an IPO, according to Babitt. 'It drives a little competitive tension to draw investors in,' he added. Illumina has already broken through the slump, announcing in June that it would buy SomaLogic for up to $425 million. Executives from some of the industry's biggest spenders — Boston Scientific and Stryker — have also signaled that they're open to continuing their M&A runs. 'We're fine and good to go,' Boston Scientific CEO Mike Mahoney said at a May investor event when questioned if the company would slow down on M&A. He explained that the company is focused on 'putting ourselves in faster-growth markets and expanding our category leadership so we can partner with customers better … We think that playbook's smart. We're effective at it. We are very good at doing integrations.' Mahoney added that the company is in 'enough businesses with so much unmet need that there's plenty of things to look at.' Meanwhile, CFO Preston Wells said in May that Stryker, which closed seven deals last year, is in a 'very good position from a liquidity standpoint, and [we] certainly still have the ability to go out and tap the debt markets if necessary and the right deal comes through.' Boston Scientific and Stryker have been some of the most active spenders in the medtech space, pursuing tuck-in deals that allow them to lead in specific business categories. Other medtech companies are expected to pursue similar strategies as the industry continues to move away from simply growing in sheer size. When discussing potential acquisitions, EY's Babitt called out surgical robotics, pulsed field ablation, structural heart and diabetes as areas that 'have a lot of growth and therefore interest.' He did not name specific companies in terms of targets or buyers. RBC's Singh believes the M&A environment is wide open. 'It's going to be all over the place,' Singh said. 'I really think that it's going to be diverse.' While the number of total transactions may not reach the heights of prior years, largely due to the months-long slowdown, the industry could see M&A pick up in the near future. 'M&A is just going to continue. I think it's the lifeblood of medtech,' Singh said. 'You're not going to pass up an opportunity because of tariffs if you can get into a multi-billion dollar market and you have an asset right in front of you.' Recommended Reading The medtech IPO window is finally open. Or is it?
Yahoo
01-07-2025
- Yahoo
North America Sports Medicine Market Forecast and Competitive Landscape Report 2025-2033 Featuring Zimmer Biomet, Stryker, Medtronic, Novartis, Smith & Nephew, CONMED, and Johnson & Johnson
The North America Sports Medicine Market is projected to reach USD 4.15 billion by 2033, growing from USD 2.50 billion in 2024 with a CAGR of 5.81% from 2025 to 2033. Key drivers include rising sports participation, an aging yet active population, and increasing awareness of fitness and preventive care. The U.S. leads the market due to its robust healthcare system, innovation in minimally invasive procedures, and high sports culture. Canada and Mexico show significant growth, supported by government initiatives and specialized programs. Challenges include practitioner shortages and gaps in injury prevention education. Major players include Zimmer Biomet, Stryker, and Johnson & Johnson. North American Sports Medicine Market Dublin, July 01, 2025 (GLOBE NEWSWIRE) -- The "North America Sports Medicine Market Share Analysis and Size - Growth Trends and Forecast Report 2025-2033" report has been added to North America Sports Medicine Market is expected to reach US$ 4.15 billion by 2033 from US$ 2.50 billion in 2024, with a CAGR of 5.81% from 2025 to 2033. The market is expanding steadily due to factors like the growing emphasis on wellness and fitness, the aging population's desire to lead active lives, and ongoing improvements in medical procedures like less invasive surgery and better rehabilitation techniques. A growing number of sports-related injuries, expanding awareness of physical fitness, and increased sports participation have all contributed to the well-established and quickly changing sports medicine market in North America. The area benefits from a sophisticated healthcare system, significant R&D investment, and a large number of specialized sports medicine specialists and facilities. Orthopedic implants, rehabilitation supplies, minimally invasive techniques, and performance-monitoring equipment are in great demand. Joint and soft tissue therapies are also becoming more and more necessary as a result of the aging population and active lifestyle trends. The market is also being shaped by technological developments like wearable technology and regenerative medicines. Because of its strong sports culture, healthcare system, and innovation pipeline, the United States leads the example, according to the Sports Accident Statistics report that LegalMatch updated in August 2022, approximately 150,000 anterior cruciate ligament (ACL) injuries occur annually in the United States. Furthermore, compared to other athletes, female basketball and soccer players experienced ACL injuries 2-8 times more frequently. The high frequency of sports-related injuries in the area is anticipated to raise demand for sports medicine and accelerate market sports medical techniques, such as joint repair and arthroscopic technology, are being developed by companies. Surgeons can now receive seamless, integrated procedural solutions thanks to new technologies, which enables them to treat patients effectively. For example, at the American Academy of Orthopedic Surgeons 2023 Annual Meeting in March 2023, Smith+Nephew presented the UltraTRAC Quad ACL Reconstruction Technique, which includes the QUADTRAC Quadriceps Tendon Harvest Guide System, X-WING Graft Preparation System, and ULTRABUTTON family of adjustable fixation devices. Surgeons can increase graft visualization and preparation efficiency thanks to sophisticated, regulated, and repeatable technology that harvests the desired quadriceps tendon tissue and lessens knee pain. Therefore, it is anticipated that such advancements in sports medicine will raise demand for it, thereby driving market Drivers for the North America Sports Medicine Market Rising Sports ParticipationOne of the main factors propelling the sports medicine market's expansion is the rise in sports participation in North America. The frequency of sports-related injuries is continuously rising as more people participate in organized sports, fitness programs, and leisure activities, spanning from school-age athletes to adults and seniors. This covers typical ailments that call for both non-surgical and surgical treatments, such as sprains, strains, fractures, and overuse injuries. The rising need for specialized sports medicine treatments has been largely attributed to the growth of high-impact activities including football, basketball, soccer, and running. Sports medicine is becoming a crucial part of contemporary athletic participation and care as a result of increased investments made by healthcare providers and athletic organizations in injury prevention, diagnosis, rehabilitation, and performance optimization Yet Active PopulationThe market for sports medicine is expanding in large part due to North America's aging but active population. Walking, swimming, cycling, and recreational sports are among the many active lifestyles that older persons are embracing in order to preserve their health and mobility. Despite its advantages, the increase in physical activity has also increased the prevalence of age-related musculoskeletal issues, such as arthritis, tendon injuries, and joint degeneration. As a result, the necessity for physical therapy, orthopedic interventions, and rehabilitation services catered to the requirements of senior citizens is increasing. These days, sports medicine is essential in helping this population stay mobile, heal from injuries, and carry on with the physical activities that promote their general Awareness of Fitness and Preventive CareIn North America, interest in sports medicine is rising as people become more conscious of fitness and preventive care. Physical exercise, appropriate training methods, and injury prevention strategies are becoming more and more important as more people place a higher priority on leading healthy lives. Professional athletes, fitness fanatics, and regular customers are all being encouraged by this change to seek professional advice from sports medicine specialists. Physical therapy, fitness regimens, and dietary counseling are examples of preventive treatment that is growing increasingly popular since it keeps people active and lowers their chance of injury. Sports medicine's involvement in proactive health management is also growing as a result of public health initiatives and media coverage regarding wellness and performance optimization, which are increasing awareness of the advantages of early intervention and continuing in the North America Sports Medicine Market Injury Prevention and Education GapsThere is still a large knowledge gap in injury prevention, especially at the amateur and grassroots levels, despite growing awareness of the issue. Safe training methods, warm-up exercises, and injury prevention approaches are not well understood by many athletes, coaches, and leisure participants. Particularly in youth sports, this lack of knowledge frequently results in avoidable injuries like sprains, strains, and stress fractures. People are more vulnerable to overuse injuries and inadequate rehabilitation if they don't receive the right advice on biomechanics, equipment, and conditioning. Sports medicine services, such as treatments and rehabilitation, are therefore in greater demand. Reducing injury rates, lowering treatment costs, and enhancing overall athlete safety may all be achieved by filling this knowledge gap through focused community-based programs and of Specialized PractitionersOne major issue facing the sports medicine industry in North America is the lack of qualified professionals. The need for specialists like orthopedic surgeons, physical therapists, and athletic trainers to manage and treat sports-related injuries is growing as more people participate in sports and physical activities. Longer wait times for individuals seeking care are the result of the supply of skilled practitioners frequently not keeping up with this rising demand. Delays in diagnosis, treatment, and rehabilitation may result from this scarcity, which could have an impact on patient outcomes and general satisfaction. Increased funding for education and training initiatives is required to meet this problem, as is the growth of telemedicine and support personnel to lessen the workload for specialists. Key Players Analyzed: Overview, Key Persons, Recent Developments, Revenue Zimmer Biomet Holdings, Inc. Stryker Medtronic Plc. Novartis AG Smith & Nephew Plc. CONMED Corporation Johnson & Johnson Services, Inc. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $2.5 Billion Forecasted Market Value (USD) by 2033 $4.15 Billion Compound Annual Growth Rate 5.8% Regions Covered North America Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. North America Sports Medicine Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share6.1 By Product6.2 By Application6.3 By End User6.4 By Countries7. Product7.1 Body Reconstruction & Repair7.2 Accessories7.3 Body Monitoring & Evaluation7.4 Body Support & Recovery8. Application8.1 Knee Injuries8.2 Shoulder Injuries8.3 Foot and Ankle Injuries8.4 Hip and Groin Injuries8.5 Elbow and Wrist Injuries8.6 Back and Spine Injuries8.7 Others9. End User9.1 Hospitals9.2 Ambulatory Surgery Centers9.3 Physiotherapy Centers and Clinics10. Countries10.1 United States10.2 Canada10.3 Mexico10.4 Rest of North America11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Sports Medicine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data